Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: SDR-SI who wrote (730)	9/9/1998 5:52:00 PM
From: Hong-Lee Yu	Read Replies (1) \| Respond to of 1686

Steven, I agreed. This agreement is a win-win situation for both companies to leverage strength. Last year, I was under impression that Merck is going to help Biogen to build infrastructure in Japan when Merck announced the license of VLA-4. It surely looks like the street is expected that Biogen either meets or beats the expectations. The confidence is very high. Most analysts have 65-75 target price. The average expected revenues for Avonex in 1999 is about 450M. This seems low. We should know more about it when Q3 report shows up.